Dr. Rebecca Feldman on Caveolin-1 and its Potential in Breast Cancer Treatment
Rebecca Feldman, PhD, molecular science liaison/research scientist, Caris Life Sciences, discusses caveolin-1, which has the potential to play a major role in the treatment of breast cancer.
Rebecca Feldman, PhD, molecular science liaison/research scientist, Caris Life Sciences, discusses caveolin-1, which has the potential to play a major role in the treatment of breast cancer.
Feldman says that by targeting caveolin-1, medical professionals could potentially restrict the growth of breast cancer in a patient. She adds that by targeting caveolin-1 and restricting breast cancer growth, new treatments that target EGFR and PDGFRA could also become a possibility. This is due to caveolin-1’s role of signaling processes on the molecular level.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
